Table 2.
Characteristic | n = 262 | Frequency (%) |
---|---|---|
Sex | ||
Male | 163 | 62 |
Female | 99 | 38 |
Age (years) | ||
Median | 14 | |
Range | 1–25 | |
Performance status score | ||
ECOG 0 | 75 | 29 |
ECOG 1 | 127 | 48 |
ECOG 2 | 50 | 19 |
Unavailable | 10 | 4 |
Tumor location | ||
At diagnosis | ||
Local | 171 | 65 |
Metastatic | 88 | 34 |
Unavailable | 3 | 1 |
At study enrollment | ||
Local | 84 | 32 |
Metastatic | 173 | 66 |
Unavailable | 5 | 2 |
Baseline laboratory values (mean, standard deviation) | ||
ANC (× 103/mm3) | 4.7 | 3.1 |
Hemoglobin (g/dl) | 11.8 | 1.8 |
Platelets (× 103/mm3) | 253 | 112 |
Total bilirubin (mg/dl) | 0.5 | 0.46 |
Prior regimens | ||
Median | 2 | |
Range | 0–9 | |
Prior radiation | ||
Yes | 190 | 73 |
No | 68 | 26 |
Unavailable | 4 | 1 |
Prior stem cell transplantation | ||
Yes | 50 | 19 |
No | 210 | 80 |
Unavailable | 2 | 1 |
Daily narcotic use | ||
Yes | 43 | 16 |
No | 207 | 79 |
Unavailable | 12 | 5 |
Concomitant medication | ||
Median | 1 | |
Range | 0–12 |
Abbreviations: ANC, absolute neutrophil count; ECOG, Eastern Cooperative Oncology Group.